Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT06269133
- Locations
- 🇺🇸
Regeneron Research Facility, Tarrytown, New York, United States
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 560
- Registration Number
- NCT06246916
- Locations
- 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 391
- Registration Number
- NCT06237309
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Oost-Vlaanderen, Belgium
🇧🇪Algemeen Ziekenhuis St Jan Brugge Oostende Av, Bruges, West Flanders, Belgium
🇧🇪Centre Hospitalier Regional de la Citadelle, Liege, Belgium
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 520
- Registration Number
- NCT06190951
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 470
- Registration Number
- NCT06149286
- Locations
- 🇩🇪
Clinic Frankfurt (Oder), Frankfurt, Hesse, Germany
🇹🇷Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT06140524
- Locations
- 🇪🇸
Hospital Sant Pau, Barcelona, Spain
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT06137482
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, Canterbury, New Zealand
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06132191